DDInter825 DDInter704
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Glimepiride {u} (Compound) causes {v} (Side Effect) Erythropenia
Erythropenia {u} (Side Effect) is caused by {v} (Compound) Everolimus
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Glimepiride {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Glimepiride {u} (Compound) causes {v} (Side Effect) Somnolence
Somnolence {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) downregulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Everolimus
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Glimepiride {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Glimepiride {u} (Compound) resembles {v} (Compound) Chlorpropamide
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Everolimus
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Glimepiride (Compound) causes Erythropenia (Side Effect) and Erythropenia (Side Effect) is caused by Everolimus (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Glimepiride (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Glimepiride (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Everolimus (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Glimepiride (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Everolimus (Compound)
Glimepiride (Compound) resembles Chlorpropamide (Compound) and Chlorpropamide (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Everolimus (Compound)